Q3 2024 CVRx Inc Earnings Call Transcript
Key Points
- CVRx Inc (CVRX) reported a 27% increase in total revenue for Q3 2024, reaching $13.4 million compared to the same period last year.
- The company secured significant reimbursement wins, including a higher DRG payment for inpatient procedures and the approval of category one CPT codes.
- The number of active implanting centers increased to 208, up from 159 a year ago, indicating expanded market presence.
- CVRx Inc (CVRX) launched a comprehensive educational program for heart failure fellows, aiming to increase awareness and adoption of Barostim therapy.
- The company strengthened its leadership team with the addition of experienced executives, enhancing strategic planning and execution capabilities.
- Net loss for Q3 2024 was $13.1 million, an increase from $9 million in the same period last year.
- SG&A expenses rose by 38% to $21.6 million, driven by increased compensation, stock-based compensation, travel, and advertising expenses.
- Interest expense increased by $0.5 million due to higher borrowings under the term loan agreement.
- Despite revenue growth, the gross margin slightly decreased from 84% to 83% year-over-year.
- The company narrowed its full-year revenue guidance, indicating potential challenges in meeting earlier expectations.
Welcome to CV RXQ 3, 2024 earnings call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation.
If anyone should require operator assistance during the conference, please press star and zero on your telephone keypad as a reminder, this conference is being recorded.
I would now like to turn the call over to Mike Valley. Thank you and over to you.
Good afternoon. Thank you for joining us today for CV R X's third quarter, 2024 earnings conference call.
Joining me on today's call are the company's President and Chief Executive Officer Kevin Hikes and Chief Financial Officer Jared Osho.
The remarks today will contain forward-looking statements including statements about financial guidance.
The statements are based on plans and expectations as of today which may change over time.
In addition, actual results could differ materially due to a number of risks and uncertainties including those
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
